Bladder Cancer: A Study of Enfortumab Vedotin for Patients With Locally Advanced or
Metastatic Urothelial Bladder Cancer (EV-201)
How does enfortumab vedotin affect patients with urothelial cancer?
Basic Study Information
Purpose:Location: Cancer Center
If you choose to take part in this study, the study treatment cycle is 28-days. You
will receive treatment with enfortumab vedotin on Day 1, 8, and 15 of each treatment
cycle. Enfortumab vedotin is given as an infusion into a vein (over about 30 minutes).
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03219333?term=SGN22E-001&rank=1
Study Reference #: IGUB17080
Lead Researcher (Principal Investigator)
Lead Researcher: Chunkit Fung
Study Contact InformationStudy Coordinator: Ayesha Khan
Phone: (585) 275-3351
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search